Pfizer’s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial

by Reshma Anand on  November 26, 2015 at 5:52 PM Corporate News
RSS Email Print This Page Comment
The US-based drug maker's lyrica developed to treat post-traumatic neuropathic pain has shown reduced efficacy in its final Phase III trial stage.
Pfizer’s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial
Pfizer’s Neuropathic Pain Drug Shows Reduced Efficacy in Its Phase III Trial

Currently there is no FDA-approved drug for treating chronic nerve pain caused by traumatic accidents or surgeries. The company had high hopes on this already existing FDA-approved drug Lyrica. But it has showed efficacy equal to only that of the placebo. The phase III trial is the final trial conducted by the drug developers for obtaining its approval from the FDA.

The generic name of Lyrica is Pregabalin and it was originally developed to treat general anxiety disorder and epilepsy. The drug has been already approved by the FDA for treating nerve pains caused due to various conditions such as diabetes, shingles, spinal cord injuries, fibromyalgia and epilepsy.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Signature Drug Toxicity Placebo Effects: Rare Insights Thoracic Outlet Syndrome Exercising Tips For Nerve Pain Relief 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive